Abstract: Objective To observe the efficacy of Oxaliplatin (OXA) combined with Vinorelbine (NVB) or Gemcitabine (GEM) on Cisplatin (DDP) plus Paclitaxel (PTX) or Docetaxel (DOC) resistant or refractory advanced non-small cell lung cancer (NSCLC).Methods Sixty patients with DDP plus PTX or DOC resistant or refractory NSCLC were divided randomly into group NO (NVB plus OXA) and group GEMOX (GEM plus OXA).Thirty patients in group NO were treated with NVB 25mg/m2 at d1 and d8,and OXA 100mg/m2 at d1.Thirty patients in group GEMOX were treated with GEM 1000mg/m2 at d1 and d8,and OXA 100mg/m2 at d1.The drugs were given intravenously,and the treatments were repeated once every three weeks.Results In group NO,five patients achieved a partial response (PR),thirteen patients achieved a stable disease (SD),and twelve patients achieved a progress disease (PD).The overall response rate (ORR) was 16.7%,the disease control rate (DCR) was 60.0%,and the time to progression (TTP) was 3.3 months.In group GEMOX,6 patients achieved PR,11 patients achieved SD,13 patients achieved PD.The ORR was 20.0%,the DCR was 56.7%,and the TTP was 3.4 months.There was no significantly statistic difference between group NO and group GEMOX.The major adverse effects in both groups were neutropenia and peripheral sensory neuropathy,and there was no significantly statistic difference between the two groups either.Conclusions It is effective to treat DDP and PTX or DOC resistant or refractory advanced NSCLC by OXA combined with NVB or GEM.

Key words: Lung neoplasm/chemotherapy, Oxaliplatin, Vinorelbine, Gemcitabine, Paclitaxel